

1 **Planning of spatially-oriented locomotion following focal brain damage in**  
2 **humans: a pilot study.**

3

4

**Supplementary Material**

5

6 **Methods**

7

8 Protocol

9

10 The experiments took place in a laboratory of dimensions 8.7 x 6 x 3.3 meters (length, width  
11 and height respectively). The protocol was similar to the one used in our previous studies [see  
12 1, 2]. Briefly, participants had to start from one of three fixed positions in the laboratory (left,  
13 center or right) and to walk towards a distant target indicated by an arrow placed on the  
14 ground (see figure 1A of the main manuscript). The dimensions of the arrow were 1.20 x 0.25  
15 meters (length and width, respectively). The arrow was placed at a specific (x,y) position in  
16 the room with a particular orientation (South, East, North and West, respectively S, E, N and  
17 W). In the blindfolded condition, the participant first observed the arrow while standing at the  
18 starting position. This observation period typically lasted less than 3 seconds. When he (or  
19 she) was ready, he closed his eyes and attempted to complete the task without vision. The  
20 starting signal was given by the experimenter by touching the participant shoulder with his  
21 hand (for both “visual” and “blindfolded” conditions).

22 During blindfolded walking, the experimenter removed the arrow in order to avoid any tactile  
23 feedback. Once the participant had completely stopped, he was asked to keep his eyes closed  
24 while the experimenter took his hand and guided him randomly for a few seconds in the  
25 laboratory before stopping at a random position. He was then allowed to re-open his eyes and  
26 to go back to the starting position. This procedure prevented participants from visual feedback  
27 during both task and post-task execution (avoiding in this way any spatial calibration of a  
28 particular displacement using kinaesthetic cues). Participants completed two to three trials  
29 before the experiment actually started in order to be familiar with the task and to dispel any  
30 fear of hitting the walls during blindfolded trials. They were aware that one of the  
31 experimenters (or a physiotherapist for patients) was present in the room during the whole  
32 trial duration to prevent any fall or contact with the wall. While the experimenter had to

1 intervene 1 or 2 times (out of 114 repetitions per participant) in few participants to prevent  
2 hitting the wall, none of them reported having felt fear during movement execution.

3 For a particular starting position, we asked participants to start walking the first step straight  
4 ahead (orthogonal to the laboratory X axis) to make sure that they all begun the task in the  
5 same conditions (both with vision and blindfolded). They were asked to enter the arrow by the  
6 shaft and to stop walking when at the tip of the (visible or memorized) arrow. This allowed us  
7 controlling for the final walking position and direction. Except for these instructions, no  
8 specific restriction relative to the path to follow was provided to participants who walked at  
9 their preferred speed. The angular displacement of the body in space induced by the different  
10 orientations of the arrow ranged between  $-180^\circ$  to  $180^\circ$  (see figure 1B).

11

12 Analysis

13

14 Whole-body trajectories

15 The average trajectory  $[x_{av}(t), y_{av}(t)]$  was defined by

$$x_{av}(t) = \frac{1}{N} \sum_{i=1}^N x_i(t); y_{av} = \frac{1}{N} \sum_{i=1}^N y_i(t) \quad (1)$$

16 where N corresponds to the number of trajectories recorded for a given target.

17 The variability of a particular *actual* trajectory around the *average* trajectory was measured  
18 using the instantaneous trajectory deviation (TD):

$$TD(t) = \sqrt{\frac{1}{N-1} \sum_{i=1}^N (x_i(t) - x_{av}(t))^2 + (y_i(t) - y_{av}(t))^2} \quad (2)$$

19

20 The Average and Maximum Trajectory Deviations (ATD, MTD) of each *actual* trajectory  
21 around the *average* trajectory were given by:

$$\text{ATD}(t) = \underset{0 \leq t \leq 1}{\text{mean}} \text{TD}(t) \quad , \quad \text{MTD}(t) = \underset{0 \leq t \leq 1}{\text{max}} \text{TD}(t) \quad (3)$$

1

2 Variance ellipses were calculated by principal component analysis. The variance ellipse at  
 3 time  $t$  is centred at  $[x_{\text{av}}(t), y_{\text{av}}(t)]$ . Its orientation and size indicate how the  $[x_i(t), y_i(t)]$  ( $I =$   
 4  $1, \dots, N$ ) are distributed around  $[x_{\text{av}}(t), y_{\text{av}}(t)]$ . Note that  $r_1(t)^2 + r_2(t)^2 = \text{TD}(t)^2$  where  $r_1$  and  $r_2$   
 5 are the lengths of the ellipse's semi major and semi minor axes [3].

6

#### Comparison of trajectories in two conditions/groups of participants

7 We also compared the average trajectories recorded in two conditions (VI and BF) or between  
 8 patients (P) and controls (C) for a same condition. For this, we defined, for each target, the  
 9 instantaneous Trajectory Separation (TS) as

$$\text{TS}_{\text{A/B}}(t) = \sqrt{(x_{\text{A}}(t) - x_{\text{B}}(t))^2 + (y_{\text{A}}(t) - y_{\text{B}}(t))^2} \quad (4)$$

10

11 where  $(x_{\text{A}}, y_{\text{A}})$  and  $(x_{\text{B}}, y_{\text{B}})$  denote the average trajectories respectively in condition/group A  
 12 and in condition/group B. We then defined the Average and Maximal Trajectory Separation  
 13 (ATS, MTS) as described in (3).

14

#### *Temporal attributes of the locomotor trajectories*

15

#### Whole-body velocity profiles

16 The computation of the velocity profiles and the variability around the mean velocity profile  
 17 was devoted to investigate whether participants varied their walking speed at similar  
 18 instants/positions along the trajectory. We thus defined the normalized velocity profile  $v_i$  and  
 19 the average normalized velocity profile  $v_{\text{av}}$  as follows

$$v_i = \frac{\sqrt{\dot{x}_i^2 + \dot{y}_i^2}}{\int_0^1 \sqrt{\dot{x}_i^2 + \dot{y}_i^2} dt} ; v_{\text{av}} = \frac{1}{N} \sum_{i=1}^N v_i \quad (5)$$

20

1 Next, the instantaneous Velocity Deviation (VD) was defined as:

$$VD(t) = \sqrt{\frac{1}{N-1} \sum_{i=1}^N (v_i(t) - v_{av}(t))^2} \quad (6)$$

2

3 We defined the Average and Maximal Velocity Deviation (AVD, MVD) as described in (3).

4

## 5 **Results**

6

7 Walking speed, traveled distances and walking durations

8 The average walking speeds, traveled distances and walking durations are presented in the  
9 figures 6A, 6B and 6C.

10

### *Walking speed*

11 On average, hemiparetic patients walk more slowly than healthy controls and non hemiparetic  
12 brain lesion patients [13]. We observed the same group effect here: the mean walking speed  
13 of CO was equal to  $0.98 \pm 0.11$  and  $0.85 \pm 0.12$  m/s (visual and blindfolded trials,  
14 respectively) while it was equal to  $0.88 \pm 0.15$  and  $0.74 \pm 0.15$  m/s in PN and to  $0.59 \pm 0.19$   
15 and  $0.47 \pm 0.17$  m/s in PH ( $F(1, 16)=14,879$ ,  $p<0.01$ ). We also observed a significant effect of  
16 the category of trajectories ( $F(10, 160)=58,394$ ,  $p<0.01$ ) on the walking speed (figure 6A),  
17 with the highest speeds being reached for the second and third straight targets (ST) and the  
18 lowest speeds being reached for the four most angled (HC) targets. The visual condition also  
19 significantly affected the walking speed ( $F(1, 16)=121,8$ ,  $p<0.01$ ). The (category x vision)  
20 interaction effect was significant ( $F(10, 160)=8,0425$ ,  $p<0.01$ ) while the (category x group)  
21 interaction effect was not significant ( $p>0.05$ ). We did not observe any other interaction  
22 effect. The effect of hemiparesis on the walking speed was assessed by performing ANOVA  
23 on the patients' group. This effect was significant ( $F(1, 8)=6,87$ ,  $p=0.03$ ): PH walked at a  
24 significantly lowest speed than PN. We observed here a significant (category x hemiparesis)  
25 interaction effect ( $F(10, 80)=2,149$ ,  $p=,029$ ) with walking speeds being nearly constant in the  
26 PH sub-group across the 11 tested categories of trajectories. However, the individual  
27 inspection of the walking speeds within each sub-group of patients revealed that PH patients  
28 P07 and P09 had walking speeds comparable to that of PN. This effect of hemiparesis can

1 thus be attributed to PH patients P03, P04 and P08. Thus, hemiparesis significantly reduced  
2 the walking speed (compared to PN) which was constant across straight and angled targets for  
3 these three PH patients only.

#### 4 *Traveled distances*

5 While these parameters naturally differ as a function of targets positions (the eleven  
6 categories of targets along the axis of abscissas), traveled distances (figure 6B) were not  
7 found to significantly differ across groups ( $p > .05$ ). However, traveled distances were  
8 significantly longer for blindfolded (BF) compared to visual (VI) conditions, as revealed by  
9 the ANOVA tests ( $F(1, 16) = 7,35, p < .05$ ). This is particularly noticeable for angled targets  
10 (categories LC, MC and HC) for both groups. This observation confirms oral reports of most  
11 participants who expressed no “fear of hitting the wall” (see Methods): indeed, the average  
12 distance traveled during blindfolded trials is comparable to that of visual trials. In any cases,  
13 the difference between the VI and BF traveled distances never exceeds one meter even for the  
14 most distant targets. No interaction effect (group x vision) was observed ( $p > .05$ ).

#### 15 *Walking durations*

16 In contrast with the walking distances, the walking durations (figure 6C) needed to complete  
17 the task were found to be significantly longer in patients compared to healthy participants  
18 ( $F(1, 16) = 7,82, p < .05$ ). Similarly, all participants walked a longer time to complete the task  
19 during blindfolded trials ( $F(1, 16) = 15,52, p < .01$ ). However, the ANOVA comparison did not  
20 reveal an interaction effect (Group x Vision). The group effect seems to be mainly driven by  
21 the hemiparetic patients (see figure 6C). However, the ANOVA could not reasonably be  
22 performed for the patients group as the Mauchly test for sphericity was positive (the  
23 variances of the patients' group were not homogeneous). Detailed inspection of the individual  
24 data (not shown) showed that walking durations are usually twice longer for the PH patients  
25 (compared to PN) except for patients P07 and patient P09 (who walked at a speed comparable  
26 to PN, see *Walking speed* section).

#### 27 *Effect of the turning direction on the traveled distances and the walking durations*

28 For this analysis, we added one level of comparison of the walking parameters by grouping  
29 together the targets including only left or right turns. The performed ANOVA comparisons  
30 did not reveal any significant effect of the turning direction on the traveled distances and  
31 walking durations ( $p > .05$ ).

## 1 Stepping behaviour

2 Here, we further analyze the spatial and temporal aspects of locomotion at the level of the  
3 locomotor/stepping pattern. In particular, all PH patients had right-sided hemiparesis. We thus  
4 tested whether the number of left (non-paretic in PH patients) and right (paretic) steps as well  
5 as the non-paretic and paretic steps' length/duration ratios varied across groups.

### 6 *Number of steps to complete the task*

7 The ANOVA comparisons did not reveal any effect of the side ( $p > .05$ ), or interaction effect  
8 (Side x Group or Side x Group x Category,  $p > .05$ ) on the number of steps. This observation  
9 revealed no asymmetry of hemiparetic gaits in terms of number of non-paretic and paretic  
10 steps across all targets (including those inducing non-paretic or paretic turns). We thus pooled  
11 together the non-paretic and paretic steps (figure 7A). Naturally, the number of steps varied as  
12 a function of the categories (which were defined based on the target positions). More  
13 interestingly, we observed that the total (left and right, or non-paretic and paretic in PH  
14 patients) number of steps was systematically higher for patients ( $F(1, 16) = 12,29$ ,  $p < .01$ ) and  
15 for blindfolded trials ( $F(1, 16) = 22,78$ ,  $p < .01$ ). We also observed an interaction effect (group x  
16 vision:  $F(1, 16) = 4,76$ ,  $p < .01$ ), explained by a higher effect of the visual condition in patients  
17 (see figure 7A). As previously observed for the walking duration parameter, the ANOVA  
18 could not reasonably be performed for the patients group as the Mauchly test for sphericity  
19 was positive (the variances of the patients' group were not homogeneous). Detailed inspection  
20 of the individual data (not shown) showed that the number of steps to complete the task was  
21 systematically higher (across categories and visual conditions) for all PH patients (compared  
22 to PN) but patients P07 and P09.

### 23 *Step Length Ratio*

24 Although the step length was significantly shorter (by about 0.3 meter,  $1.17 \pm 0.13$  vs  $0.89 \pm$   
25  $0.22$  meter on average for healthy participants vs patients, respectively) in patients compared  
26 to healthy participants ( $F(1, 16) = 17,90$ ,  $p < 0.01$ ), we did not observe any effect of the side (left  
27 /right steps, or non-paretic/paretic steps in PH) on the mean step length ( $p > 0.05$ ). We also  
28 observed an effect of vision with steps shorter (by about 0.15 meter) in BF trials compared to  
29 VI trials ( $F(1, 16) = 48,19$ ,  $p < .01$ ). No interaction effect (vision x group) was observed ( $p > .05$ ).  
30 We thus compared (left/right or non-paretic/paretic) step length ratios across categories,  
31 groups and visual conditions. This ratio was close to 1 (figure 7B) and no effect of the

1 category ( $p>.05$ ) or the visual condition ( $p>.05$ ) was observed. However, we observed a  
2 significant group effect ( $F(1, 16)=6,96, p<.05$ ) on the step length ratios SLR, although ratios  
3 ranged between 0.99 and 1.02 on average (for healthy participants vs patients, respectively).  
4 No interaction effect (category x group, category x vision, group x vision, or category x vision  
5 x group,  $p>.05$ ) was observed. The effect of hemiparesis on the SLR was assessed by  
6 performing ANOVA on the patients' group. No statistically significant effect of hemiparesis  
7 (and no interaction effect with vision or category of trajectories,  $p>0.05$ ) on the SLR was  
8 observed. Thus, step length does not seem to be a strong marker of gait asymmetry in PH  
9 patients [4].

#### 10 *Stance Duration Ratios*

11 The mean stance phase duration was longer (by about 0.21 second,  $1.24 \pm 0.18$  vs  $1.45 \pm 0.30$   
12 seconds on average for healthy participants vs patients, respectively) in patients compared to  
13 healthy participants. However, we could not compare the mean stance phase durations (nor  
14 the stance phase durations ratios SDR) across groups because the Mauchley test for sphericity  
15 was positive (the variances of the whole population of participants group were not  
16 homogeneous). We therefore performed this test separately for the healthy and for the  
17 patients' groups only and the tests were negative in both cases. The ANOVA comparisons  
18 performed on the CO group revealed a statistically significant effect of the category of  
19 trajectories ( $F(10, 90)=4,42, p<0.01$  – shorter stance phase durations for the straight targets  
20 ST), of vision ( $F(1, 9)=13,21, p<0.01$  – longer stance phase durations for BF trials) and a  
21 significant interaction (category x vision) effect ( $F(10, 90)=2,67, p<0.01$ ) on the mean stance  
22 phase durations. The ANOVA comparisons performed on the patients' group revealed no  
23 significant effect of hemiparesis ( $p>0.05$ ), a statistically significant effect of the limb side  
24 ( $F(1, 8)=7,67, p=0.024$ ), of the visual condition ( $F(1, 8)=10,89, p=0.011$  – longer stance phase  
25 durations for BF trials) and the category of trajectory ( $F(10, 80)=4,02, p<0.01$  – shorter stance  
26 phase durations for the straight targets ST), and a significant interaction (hemiparesis x limb  
27 side) effect ( $F(1, 8)=14,11, p<0.01$ ) on the stance phase duration. The stance phase duration  
28 of the paretic limb in PH patients was thus significantly shorter than the one of the non-paretic  
29 limb. The stance phase duration ratios (SDR, figure 7C) confirmed these observations. A SDR  
30 close to 1 reveals perfect gait symmetry at the level of the stance phase. These were higher  
31 than 1 only in PH patients (around 1.17 on average). The ANOVA comparisons of the stance  
32 duration ratios (SDR) across categories and visual conditions revealed no statistically  
33 significant difference in the CO group, indicating symmetric gaits in CO. The ANOVA

1 comparisons performed on the patients group revealed a statistically significant effect of  
2 hemiparesis ( $F(1, 8)=9,85, p=0.013$ ) on the SDR without any interaction effect. However,  
3 visual inspection of individual data revealed the opposite phenomenon for the hemiparetic  
4 patient P09 who had SDR systematically around 0.8 (paretic limbs had longer stance phase  
5 durations). Thus, gait asymmetries frequently reported at the level of step duration [4] are  
6 mainly explained by stance duration asymmetries (whatever the limb under consideration),  
7 confirming the findings of a previous study [see 5].

### 8 *Effect of the turning direction on the stepping pattern*

9 The turning direction did not affect any of the computed step parameters ( $p>.05$ ), as observed  
10 in a previous study [see 5].

11

## 12 **References**

- 13 [1] Hicheur H, Pham QC, Arechavaleta G, Laumond JP, Berthoz A. The formation of trajectories  
14 during goal-oriented locomotion in humans. I. A stereotyped behaviour. *EurJ Neurosci.* 2007;26:2376-  
15 90.  
16 [2] Pham QC, Hicheur H. On the open-loop and feedback processes that underlie the formation of  
17 trajectories during visual and nonvisual locomotion in humans. *JNeurophysiol.* 2009;102:2800-15.  
18 [3] Pham QC, Hicheur H, Arechavaleta G, Laumond JP, Berthoz A. The formation of trajectories  
19 during goal-oriented locomotion in humans. II. A maximum smoothness model. *EurJ Neurosci.*  
20 2007;26:2391-403.  
21 [4] Lauziere S, Betschart M, Aissaoui R, Nadeau S. Understanding Spatial and Temporal Gait  
22 Asymmetries in Individuals Post Stroke. *Int J Phys Med Rehabil.* 2014;2.  
23 [5] Godi M, Nardone A, Schieppati M. Curved walking in hemiparetic patients. *Journal of*  
24 *rehabilitation medicine.* 2010;42:858-65.

25

26

27


1

2 S1

S2

S3

S4



3


4

5 S4

S6

S7

S8




6

7

8 S09

S10




9

10


11 **Figure 5:** Images from MRI/CT indicating the core brain lesions in each patient (Left is on the right  
 12 side) - see Table 1 of the main paper for a detailed description of the lesioned areas.

13



1

2 **Figure 6:** Walking speeds (A), traveled distances (B) and walking durations (C) across targets (C1N  
 3 to R3S) and visual conditions. L and R indicate Left and Right turns, respectively - 1, 2 and 3 indicate  
 4 target positions (see figure 1 of the main manuscript) - S, E, W and N indicate South, East, West and  
 5 North final target orientations. Categories ST, LC, MC and HC correspond to straight-ahead walking,  
 6 Low-Medium-High Curvature walking trajectories, respectively. Red and black colors correspond to  
 7 visual and blindfolded trials, respectively (see insert of the top-left corner of B for further information  
 8 about the color code). Note the longer durations (slowest walking speeds) necessary to perform the  
 9 task and the weak effect of targets on the walking speeds in PH patients only (see text for results of the  
 10 statistical comparisons across groups, targets and visual conditions).



1

2 **Figure 7:** Number of steps to complete the task (A), left/right (non hemiparetic limb/paretic limb in  
 3 PH patients) step length ratio (B) and stance phase duration ratio (C) across targets and visual  
 4 conditions (same color code as figure 5). The horizontal dashed line in B and C indicate a perfect gait  
 5 symmetry (ratio = 1). Note the higher number of steps (A) to perform the task and the clear gait  
 6 asymmetry observed at the temporal (C) but not at the spatial (B) level in PH patients only only (see  
 7 text for results of the statistical comparisons across groups, targets and visual conditions).